FIX LONG STUDY: A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF SPK 9001 (RAAV SPARK100 HFIX PADUA) IN INDIVIDUALS WITH HEMOPHILIA B
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Fidanacogene-elaparvovec (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Acronyms FIX-LONG Study
- Sponsors Pfizer; Spark Therapeutics
- 02 Dec 2019 Planned End Date changed from 8 Jun 2026 to 6 Oct 2026.
- 02 Dec 2019 Planned primary completion date changed from 8 Jun 2026 to 6 Oct 2026.
- 10 Aug 2019 Planned End Date changed from 16 May 2026 to 8 Jun 2026.